retatrutide clinical trial south korea Experimental Obesity Drug Also Effective in Treating Fatty Liver SURMOUNT‐1 study design. This is

Prior authorizations, formulary changes, and high out-of-pocket costs can delay access or interrupt treatment

Conclusion Outside of addiction, the psychiatric effects of these drugs appear limited

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

The injection technique and storage are broadly similar between Mounjaro and Wegovy, but there are a few subtle differences worth knowing if youre switching